NCT05897957
Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01
Enrolling by Invitation
Not specifiedAges 50–78ObservationalBlueRock Therapeutics
~12 participants
Updated 2024-04-12 on ClinicalTrials.gov
At a glance
Recruiting sites
0 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total SAEs and total number of subjects with at least 1 SAE
Measured over Baseline through 5 years post-transplantation
Conditions
Where it's being run
3 sites across 3 statesCalifornia1
New York1
Ontario1
Study leadership
- Nauman Abid, MD · STUDY_DIRECTOR · BlueRock Therapeutics LP
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subject received BRT-DA01 in Study MSK-DA01-101 (ie, parent study) and will have completed or discontinued the parent study
Subject must be willing and able to provide written informed consent for the BRT-DA0-501 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures
What this trial measures
- Total SAEs and total number of subjects with at least 1 SAEBaseline through 5 years post-transplantation
Total SAEs and total number of subjects with at least 1 SAE related to cellular drug product